Key Highlights
• IBio’s IBIO-610 reduced active Activin E levels by 98% at week 4 in obese non-human primates after a single dose.
• The drug maintained 97% suppression of Activin E through eight weeks, supporting long-acting antibody potential.
• When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% compared to semaglutide alone.
• Full data will be shared at an upcoming scientific conference in late 2026.
Drug Shows Strong Target Engagement
IBio (NYSE American: IBIO) announced preclinical findings for its obesity candidate IBIO-610, demonstrating near-complete suppression of active Activin E in non-human primates. A single administration of the antibody led to a 98% reduction in circulating levels of the target protein within four weeks. The results suggest the therapy could offer a long-acting treatment option for metabolic disorders, potentially requiring less frequent dosing than existing approaches.
Durable Effect Demonstrated
The drug’s impact persisted throughout the eight-week study period. Active Activin E levels remained suppressed by 97% at the final time point, with measurements falling below the assay’s detection limits. The sustained inhibition reinforces the potential of IBIO-610 as a leading candidate in its target class, offering prolonged biological activity.
Lean Mass Preservation Highlighted
In the primate model, IBIO-610 demonstrated an ability to support fat-selective weight loss while minimizing muscle loss. When used alongside semaglutide, the drug reduced lean mass loss by 73% compared to semaglutide alone. These findings position IBIO-610 as a potential standalone therapy and a complementary agent to current GLP-1-based treatments, addressing a key limitation of existing weight loss drugs.
Combination Therapy Potential
The study revealed that IBIO-610 enhanced fat reduction outcomes when paired with semaglutide. Animals receiving the combination exhibited greater reductions in visceral and total fat compared to those treated with semaglutide alone. The results highlight the drug’s potential role in advancing obesity treatment strategies, particularly for patients seeking improved body composition outcomes.
Conference Presentation Planned
IBio will present the complete dataset at a major scientific conference later this year. The presentation will offer additional insights into the drug’s mechanism of action and preclinical performance, providing further context for its therapeutic potential.
Activin E as a Novel Target
IBIO-610 represents a first-in-class antibody targeting Activin E, a protein involved in metabolic regulation. The drug’s ability to selectively reduce fat while preserving lean tissue distinguishes it from other obesity therapies. This novel mechanism has drawn attention from researchers and analysts as a potential solution to challenges in long-term weight management.
Regulatory Pathway Considerations
While the preclinical results are encouraging, iBio has not yet begun human trials for IBIO-610. The company continues to focus on advancing the candidate through additional development stages. Stakeholders are closely watching progress toward potential clinical studies and future partnership opportunities as the program evolves.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...